We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




The Immune System Reacts More Vigorously to Hydrophobic Nanoparticles

By LabMedica International staff writers
Posted on 10 Apr 2012
A recent study showed that the degree to which the immune system reacts to foreign nanoparticles is directly related to how hydrophobic the particles are.

Understanding the interactions of nanomaterials with the immune system is essential for the engineering of new macromolecular drug or vaccine delivery systems. More...
However, a systematic study of immune activation has been difficult to perform due to the complex structure of most macromolecular probes.

In the current study, investigators at Tel Aviv University (Israel) fabricated pure gold nanoparticles that were two nanometers in diameter. In the unmodified state, the nanoparticles were not recognized by immune cells. Thus, the effect of any change in the surface of the particles could be detected.

The investigators manufactured a series of gold nanoparticles that presented a linear increase in hydrophobicity. These particles were then added to cultures of immune spleen cells (splenocytes) and injected into mice.

Results published in the February 17, 2012, online edition of the Journal of the American Chemical Society revealed that increased hydrophobicity of the nanoparticle headgroups, caused a linear increase in immune activity in the cell cultures. Consistent behavior was observed with in vivo mouse models, demonstrating the importance of hydrophobicity in immune system activation.

“We are using these gold particles to tackle the question of how the immune system recognizes different particles, which might include features such as geometry, charge, curvature, and so much more. Now that we know the tool works, we can build on it,” said senior author Dr. Dan Peer, professor of nanomedicine at Tel Aviv University. “We now have the capability of using nanomaterials to probe the immune system in a very accurate manner, a breakthrough that could revolutionize the way we understand the immune system.”

Related Links:

Tel Aviv University




Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Associate Professor Arutha Kulasinghe and non-small cell lung cancer cell (Photo courtesy of The University of Queensland)

Blood-Based Proteomic Test May Predict Treatment Response in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death, with non-small cell lung cancer (NSCLC) accounting for most cases. Treatment decisions are often made without a clear indication of how a patient... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.